Beril Altun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Beril Altun has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ela Kadioglu
Gazi University, Faculty of Pharmacy, Department of Toxicology, Ankara, Turkey
3 shared publications - Alptekin Cetin
Üsküdar Üniversitesi
2 shared publications - Cemal Onur Noyan
Uskudar University, Istanbul, Turkey
2 shared publications - Ismet Cok
Faculty of Pharmacy, Department of Toxicology, Gazi University, Ankara, Turkey
2 shared publications - Merih Altıntaş
İstanbul Erenköy Training and Research Hospital for Psychiatry and Neurological Diseases , İstanbul , Türkiye
2 shared publications - Nesrin Dilbaz
Department of Psychiatry, Faculty of Medicine, Üsküdar University, Istanbul 34662, Türkiye
2 shared publications
Latest Publications
- Open Access
- 22 May 2025
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 50 (6) , 851-859
The possible link between endocannabinoid system gene polymorphisms and overweight/obesity susceptibility in individuals living in the Marmara Region
Objectives: Obesity is a global health problem related to reduced life quality and shorter life expectancy. Given the fact that genetic factors play a role in obesity development, studies have suggested that polymorphisms of cannabinoid receptor 1 ( CNR1 ), monoacylglycerol lipase ( MGLL ), and fatty acid amide hydrolase ( FAAH ) genes located in the endocannabinoid system (ECS) are related to overweight/obesity risk. Accordingly, we aimed to assess the genetic susceptibility to overweight/obesity in individuals with Turkish ancestral origin concerning these ECS genes. Methods: The present study comprised 194 unrelated individuals with Turkish ancestral origin living in the Marmara Region. The study population is categorized into two groups according to their body mass index (BMI) overweight/obese group (BMI≥25) and normal weight group (18.5CNR1 rs1049353 , MGLL rs60430 , and FAAH rs324420 polymorphisms was performed using the real-time polymerase chain reaction (RT-PCR). Results: The GG genotype frequency of CNR1 rs1049353 was significantly higher in overweight/obese individuals than in normal weight individuals (75.5 vs. 61.4 %, respectively; p=0.034). No difference was observed in terms of MGLL rs604300 and FAAH rs324420 polymorphisms between the groups (p>0.05). The genotype distributions of CNR1 , MGLL , and FAAH genes were compatible with the Hardy–Weinberg equilibrium (p>0.05). Conclusions: Our findings supported that individuals with AA/AG genotype of CNR1 rs1049353 have reduced overweight/obesity risk; however, neither FAAH rs324420 nor MGLL rs604300 showed any association. A relatively smaller sample size and lack of inclusion of obesity-related measurements could be considered the limitations of this study. Further research is needed to confirm or disprove our results.
- 22 May 2025
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 50 (6) , 851-859
Open AccessThe possible link between endocannabinoid system gene polymorphisms and overweight/obesity susceptibility in individuals living in the Marmara Region
Objectives: Obesity is a global health problem related to reduced life quality and shorter life expectancy. Given the fact that genetic factors play a role in obesity development, studies have suggested that polymorphisms of cannabinoid receptor 1 ( CNR1 ), monoacylglycerol lipase ( MGLL ), and fatty acid amide hydrolase ( FAAH ) genes located in the endocannabinoid system (ECS) are related to overweight/obesity risk. Accordingly, we aimed to assess the genetic susceptibility to overweight/obesity in individuals with Turkish ancestral origin concerning these ECS genes. Methods: The present study comprised 194 unrelated individuals with Turkish ancestral origin living in the Marmara Region. The study population is categorized into two groups according to their body mass index (BMI) overweight/obese group (BMI≥25) and normal weight group (18.5CNR1 rs1049353 , MGLL rs60430 , and FAAH rs324420 polymorphisms was performed using the real-time polymerase chain reaction (RT-PCR). Results: The GG genotype frequency of CNR1 rs1049353 was significantly higher in overweight/obese individuals than in normal weight individuals (75.5 vs. 61.4 %, respectively; p=0.034). No difference was observed in terms of MGLL rs604300 and FAAH rs324420 polymorphisms between the groups (p>0.05). The genotype distributions of CNR1 , MGLL , and FAAH genes were compatible with the Hardy–Weinberg equilibrium (p>0.05). Conclusions: Our findings supported that individuals with AA/AG genotype of CNR1 rs1049353 have reduced overweight/obesity risk; however, neither FAAH rs324420 nor MGLL rs604300 showed any association. A relatively smaller sample size and lack of inclusion of obesity-related measurements could be considered the limitations of this study. Further research is needed to confirm or disprove our results.
- 16 April 2024
- Published by Academician Publishing
- p. 13-34
Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates
Cannabinoids, regardless of their structure or origin, refer to chemical substances that act on cannabinoid receptors and produce pharmacological effects similar to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive ingredient of the Cannabis sativa plant. Cannabinoids, which act on the endocannabinoid system, are thought to have a potential therapeutic value in a variety of diseases and conditions due to their involvement in vital processes such as appetite, nausea, vomiting, pain sensitivity, mood and memory. To date, cannabinoids have been approved for certain indications by the United States Food and Drug Administration (FDA): refractory epilepsy (Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex), spasticity and neuropathic pain in multiple sclerosis (MS), Acquired Immune Deficiency Syndrom (AIDS)-related cachexia, and chemotherapy-induced nausea and vomiting. According to pre-clinical studies, cannabinoids are also promising for a wide range of indications such as fibromyalgia, post-traumatic stress disorder, insomnia, anxiety, cancer, and cancer-related pain. Cannabinoids are being explored as an anticancer agent in different types of cancer due to increasing evidence for their antiproliferative and antitumor effects. Scientific research that will reveal the therapeutic potential of cannabinoids, cannabinoid type/ratio, and efficacious dosage forms on an evidence-based approach are needed for non-approved indications including cancer. Foremost, the elimination of legal barriers in front of scientific research on cannabinoids will ease towards this goal. In this chapter, it is aimed to summarize the therapeutic use of cannabinoids, prospects for novel indications, and ongoing clinical trials to provide a comprehensive overview on the current state of knowledge.
- 16 April 2024
- Published by Academician Publishing
- p. 13-34
Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates
Cannabinoids, regardless of their structure or origin, refer to chemical substances that act on cannabinoid receptors and produce pharmacological effects similar to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive ingredient of the Cannabis sativa plant. Cannabinoids, which act on the endocannabinoid system, are thought to have a potential therapeutic value in a variety of diseases and conditions due to their involvement in vital processes such as appetite, nausea, vomiting, pain sensitivity, mood and memory. To date, cannabinoids have been approved for certain indications by the United States Food and Drug Administration (FDA): refractory epilepsy (Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex), spasticity and neuropathic pain in multiple sclerosis (MS), Acquired Immune Deficiency Syndrom (AIDS)-related cachexia, and chemotherapy-induced nausea and vomiting. According to pre-clinical studies, cannabinoids are also promising for a wide range of indications such as fibromyalgia, post-traumatic stress disorder, insomnia, anxiety, cancer, and cancer-related pain. Cannabinoids are being explored as an anticancer agent in different types of cancer due to increasing evidence for their antiproliferative and antitumor effects. Scientific research that will reveal the therapeutic potential of cannabinoids, cannabinoid type/ratio, and efficacious dosage forms on an evidence-based approach are needed for non-approved indications including cancer. Foremost, the elimination of legal barriers in front of scientific research on cannabinoids will ease towards this goal. In this chapter, it is aimed to summarize the therapeutic use of cannabinoids, prospects for novel indications, and ongoing clinical trials to provide a comprehensive overview on the current state of knowledge.
- Open Access
- 16 April 2024
- Published by Academician Publishing
Current Research in Pharmacy and Pharmaceutical Sciences II
Pharmacogenetics of Antidepressants: Overview of Dosing Strategies in Major Depressive Disorder Saja SAİD Gül ÖZBEY Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates Beril ALTUN The Xanthine Oxidase Inhibitory Activities of Natural-Based Compounds Targeting Gout Nurcan DEDEOĞLU The Relationship of Dementia and Diabetes Mehtap TUGRAK SAKARYA Rational Use of Drugs Dilan ÖZMEN ÖZGÜN Endocrine Therapy in Breast Cancer: Recent Advances in the Drugs Used Dilek AKSOY Strategies to Increase Solubility and Bioavailability of Drugs İrem ÇİNAR Emrah ÖZAKAR Rukiye SEVİNÇ ÖZAKAR Vesıcular Drug Delivery Systems Muhammet Enes ÖZMUTLU Rukiye SEVİNÇ ÖZAKAR Emrah ÖZAKAR Definition of Pharmacovigilance and Its Historical Development in the World and Türkiye Berna ÖZTÜRK KARAGÖZ
- 16 April 2024
- Published by Academician Publishing
Open AccessCurrent Research in Pharmacy and Pharmaceutical Sciences II
Pharmacogenetics of Antidepressants: Overview of Dosing Strategies in Major Depressive Disorder Saja SAİD Gül ÖZBEY Therapeutic Use of Cannabinoids: Clinical Overview and Recent Updates Beril ALTUN The Xanthine Oxidase Inhibitory Activities of Natural-Based Compounds Targeting Gout Nurcan DEDEOĞLU The Relationship of Dementia and Diabetes Mehtap TUGRAK SAKARYA Rational Use of Drugs Dilan ÖZMEN ÖZGÜN Endocrine Therapy in Breast Cancer: Recent Advances in the Drugs Used Dilek AKSOY Strategies to Increase Solubility and Bioavailability of Drugs İrem ÇİNAR Emrah ÖZAKAR Rukiye SEVİNÇ ÖZAKAR Vesıcular Drug Delivery Systems Muhammet Enes ÖZMUTLU Rukiye SEVİNÇ ÖZAKAR Emrah ÖZAKAR Definition of Pharmacovigilance and Its Historical Development in the World and Türkiye Berna ÖZTÜRK KARAGÖZ
- Open Access
- 8 May 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 48 (3) , 282-289
Assessment of the effects of CNR1, FAAH and MGLL gene variations on the synthetic cannabinoid use disorder
Objectives: Given that drug addiction occurs as a result of complex gene-environment interaction, a number of studies claimed that cannabinoid receptor 1 ( CNR1 ), fatty acid amide hydrolase ( FAAH ), and monoacylglycerol lipase ( MGLL ) single nucleotide polymorphisms (SNPs) are associated with the risk of substance use disorders such as cannabis, opioids, and, methamphetamine. However, scientific research on genetic susceptibility to synthetic cannabinoid addiction is limited. In this population-based case-control study, we aimed to evaluate the genetic susceptibility to synthetic cannabinoid use disorder in terms of these three endocannabinoid system genes in the Turkish population. Methods: 100 individuals diagnosed with synthetic cannabinoid use disorder according to Diagnostics and Statistical Manual of Mental Disorders-5 criteria and 100 healthy volunteers have recruited for the study. Genotyping of the CNR1 rs1049353 , FAAH rs324420 , and MGLL rs604300 SNPs was performed using Real-Time Polymerase Chain Reaction hybridization probes. Results: The patient and control groups consist of 98 % male, 2 % female, 80 % male, and 20 % female individuals, respectively. The genotype distributions were consistent with Hardy–Weinberg equilibrium for all SNPs (p>0.05). FAAH rs324420 and MGLL 604300 SNPs were genotyped for the first time in the Turkish population, and the variant allele frequencies were found as 0.205 and 0.085, respectively. Allele frequencies and genotype distributions CNR1 rs1049353 , FAAH rs324420 , and MGLL rs604300 SNPs were similar between the patient and control group (p>0.05). Conclusions: These results indicate that CNR1 , FAAH , and MGLL gene polymorphisms do not influence the risk of synthetic cannabinoid use disorder in the Turkish population.
- 8 May 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 48 (3) , 282-289
Open AccessAssessment of the effects of CNR1, FAAH and MGLL gene variations on the synthetic cannabinoid use disorder
Objectives: Given that drug addiction occurs as a result of complex gene-environment interaction, a number of studies claimed that cannabinoid receptor 1 ( CNR1 ), fatty acid amide hydrolase ( FAAH ), and monoacylglycerol lipase ( MGLL ) single nucleotide polymorphisms (SNPs) are associated with the risk of substance use disorders such as cannabis, opioids, and, methamphetamine. However, scientific research on genetic susceptibility to synthetic cannabinoid addiction is limited. In this population-based case-control study, we aimed to evaluate the genetic susceptibility to synthetic cannabinoid use disorder in terms of these three endocannabinoid system genes in the Turkish population. Methods: 100 individuals diagnosed with synthetic cannabinoid use disorder according to Diagnostics and Statistical Manual of Mental Disorders-5 criteria and 100 healthy volunteers have recruited for the study. Genotyping of the CNR1 rs1049353 , FAAH rs324420 , and MGLL rs604300 SNPs was performed using Real-Time Polymerase Chain Reaction hybridization probes. Results: The patient and control groups consist of 98 % male, 2 % female, 80 % male, and 20 % female individuals, respectively. The genotype distributions were consistent with Hardy–Weinberg equilibrium for all SNPs (p>0.05). FAAH rs324420 and MGLL 604300 SNPs were genotyped for the first time in the Turkish population, and the variant allele frequencies were found as 0.205 and 0.085, respectively. Allele frequencies and genotype distributions CNR1 rs1049353 , FAAH rs324420 , and MGLL rs604300 SNPs were similar between the patient and control group (p>0.05). Conclusions: These results indicate that CNR1 , FAAH , and MGLL gene polymorphisms do not influence the risk of synthetic cannabinoid use disorder in the Turkish population.
- 1 December 2020
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (6) , 686-697
New Therapeutic Approaches in Cystic Fibrosis
Cystic fibrosis (CF) is a hereditary, multisystemic disease caused by different mutations in the CFTR gene encoding CF transmembrane conductance regulator. CF is mainly characterized by pulmonary dysfunction as a result of deterioration in the mucociliary clearance and anion transport of airways. Mortality is mostly caused by bronchiectasis, bronchiole obstruction, and progressive respiratory dysfunction in the early years of life. Over the last decade, new therapeutic strategies rather than symptomatic treatment have been proposed, such as the small molecule approach, ion channel therapy, and pulmonary gene therapy. Due to considerable progress in the treatment options, CF has become an adult disease rather than a pediatric disease in recent years. Pulmonary gene therapy has gained special attention due to its mutation type independent aspect, therefore being applicable to all CF patients. On the other hand, the major obstacle for CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity. The advancement of 3D culture systems has made it possible to extrapolate the disease modeling and individual drug response in vitro by producing mini adult organs called "organoids" obtained from rectal cell biopsies. In this review, we summarize the advances in the novel therapeutic approaches, clinical interventions, and precision medicine concept for CF.
- 1 December 2020
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (6) , 686-697
New Therapeutic Approaches in Cystic Fibrosis
Cystic fibrosis (CF) is a hereditary, multisystemic disease caused by different mutations in the CFTR gene encoding CF transmembrane conductance regulator. CF is mainly characterized by pulmonary dysfunction as a result of deterioration in the mucociliary clearance and anion transport of airways. Mortality is mostly caused by bronchiectasis, bronchiole obstruction, and progressive respiratory dysfunction in the early years of life. Over the last decade, new therapeutic strategies rather than symptomatic treatment have been proposed, such as the small molecule approach, ion channel therapy, and pulmonary gene therapy. Due to considerable progress in the treatment options, CF has become an adult disease rather than a pediatric disease in recent years. Pulmonary gene therapy has gained special attention due to its mutation type independent aspect, therefore being applicable to all CF patients. On the other hand, the major obstacle for CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity. The advancement of 3D culture systems has made it possible to extrapolate the disease modeling and individual drug response in vitro by producing mini adult organs called "organoids" obtained from rectal cell biopsies. In this review, we summarize the advances in the novel therapeutic approaches, clinical interventions, and precision medicine concept for CF.
- Open Access
- 1 April 2020
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (2) , 235-241
Psychoactive Bath Salts and Neurotoxicity Risk
Synthetic cathinones are new designer drugs that possess hallucinogenic and psychostimulant properties, and are designed to mimic the effects of illegal substances such as cocaine, amphetamines, and 3.4-methylenedioxymethamphetamine (ecstasy) and to produce rewarding effects, circumventing existing laws and penalties. Synthetic cathinones, also referred to as 'bath salts', have become popular particularly among young people since the mid-2000s. Similar to other psychomotor stimulants, synthetic cathinones have the potential to increase monoamine concentration in the synaptic cleft by targeting the plasma membrane transporters of dopamine, norepinephrine, and serotonin. Because of their structural similarities to amphetamines, it has been suggested that synthetic cathinones may have a neurotoxicity profile similar to that of their amphetamine congeners. Therefore, it has been hypothesized that synthetic cathinones may induce neurotoxicity on monoamine nerve endings in the striatum, hippocampus, and cortex. To date, with regard to synthetic cathinone neurotoxicity, parameters such as monoamine depletion, biosynthetic enzyme inhibition, cytotoxicity, generation of reactive oxygen species, pro-oxidation status, and the ability to induce neuroinflammation were investigated in both in vitro and in vivo experimental studies. Compared with amphetamines, synthetic cathinones appear to have more moderate effects than their amphetamine congeners in terms of neurotoxic effects. However, many synthetic cathinone users take these substances simultaneously with other substances such as benzodiazepines, amphetamines, ecstasy, tetrahydrocannabinol, and ethanol and this abuse can modify their neurotoxic effects. Hence, it is important to understand the underlying mechanism of early neurotoxic effects in case of polysubstance use. In this review, we aimed to present up-to-date information on the abuse potential of synthetic cathinones, their legal status, mechanism of action, and particularly their neurotoxic effects.
- 1 April 2020
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (2) , 235-241
Open AccessPsychoactive Bath Salts and Neurotoxicity Risk
Synthetic cathinones are new designer drugs that possess hallucinogenic and psychostimulant properties, and are designed to mimic the effects of illegal substances such as cocaine, amphetamines, and 3.4-methylenedioxymethamphetamine (ecstasy) and to produce rewarding effects, circumventing existing laws and penalties. Synthetic cathinones, also referred to as 'bath salts', have become popular particularly among young people since the mid-2000s. Similar to other psychomotor stimulants, synthetic cathinones have the potential to increase monoamine concentration in the synaptic cleft by targeting the plasma membrane transporters of dopamine, norepinephrine, and serotonin. Because of their structural similarities to amphetamines, it has been suggested that synthetic cathinones may have a neurotoxicity profile similar to that of their amphetamine congeners. Therefore, it has been hypothesized that synthetic cathinones may induce neurotoxicity on monoamine nerve endings in the striatum, hippocampus, and cortex. To date, with regard to synthetic cathinone neurotoxicity, parameters such as monoamine depletion, biosynthetic enzyme inhibition, cytotoxicity, generation of reactive oxygen species, pro-oxidation status, and the ability to induce neuroinflammation were investigated in both in vitro and in vivo experimental studies. Compared with amphetamines, synthetic cathinones appear to have more moderate effects than their amphetamine congeners in terms of neurotoxic effects. However, many synthetic cathinone users take these substances simultaneously with other substances such as benzodiazepines, amphetamines, ecstasy, tetrahydrocannabinol, and ethanol and this abuse can modify their neurotoxic effects. Hence, it is important to understand the underlying mechanism of early neurotoxic effects in case of polysubstance use. In this review, we aimed to present up-to-date information on the abuse potential of synthetic cathinones, their legal status, mechanism of action, and particularly their neurotoxic effects.
- 19 September 2018
- Published by Springer Nature in Molecular Biology Reports
- Vol. 45 (6) , 2193-2199
The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population—a preliminary study
Single nucleotide polymorphisms (SNPs), the most common genetic variations in human genome, can manage the predisposition of certain complex diseases or situations such as obesity. Genetic polymorphisms also play an important role as they can impact a population’s susceptibility to being overweight or obese and developing related chronic complications such as hypertension, coronary heart disease, diabetes and cancer. The present study comprised of 193 unrelated healthy volunteers (120 females and 73 males) with Turkish origin. Only female adolescents (n = 110) were divided into 2 categories according to their BMI values as overweight (BMI ≥ 25) and normal (18.5 < BMI < 25) according to WHO classification. Genomic DNA was isolated from venous blood samples and genotyping of DENND1A rs10818854 and CYP19A1 rs2414096 variants was performed on Roche Light Cycler 2.0 Real-Time PCR platform. Serum hormone levels were analyzed by Electrochemiluminescent Immunoassay (ECLIA; Roche diagnostics). The genotype distributions were consistent with the Hardy–Weinberg equilibrium for both SNPs in the studied population (p > 0.05). The genotype distribution of DENND1A rs10818854 was determined for the first time in Turkish population and the variant allele frequency was found as 0.095. According to reduced sex hormone-binding globulin levels and increased free androgen index in the present study, obesity was linked with hyperandrogenism in female subjects. Both polymorphisms were investigated as potential genetic susceptibility markers for obesity and neither DENND1A nor CYP19A1 showed any associations.
- 19 September 2018
- Published by Springer Nature in Molecular Biology Reports
- Vol. 45 (6) , 2193-2199
The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population—a preliminary study
Single nucleotide polymorphisms (SNPs), the most common genetic variations in human genome, can manage the predisposition of certain complex diseases or situations such as obesity. Genetic polymorphisms also play an important role as they can impact a population’s susceptibility to being overweight or obese and developing related chronic complications such as hypertension, coronary heart disease, diabetes and cancer. The present study comprised of 193 unrelated healthy volunteers (120 females and 73 males) with Turkish origin. Only female adolescents (n = 110) were divided into 2 categories according to their BMI values as overweight (BMI ≥ 25) and normal (18.5 < BMI < 25) according to WHO classification. Genomic DNA was isolated from venous blood samples and genotyping of DENND1A rs10818854 and CYP19A1 rs2414096 variants was performed on Roche Light Cycler 2.0 Real-Time PCR platform. Serum hormone levels were analyzed by Electrochemiluminescent Immunoassay (ECLIA; Roche diagnostics). The genotype distributions were consistent with the Hardy–Weinberg equilibrium for both SNPs in the studied population (p > 0.05). The genotype distribution of DENND1A rs10818854 was determined for the first time in Turkish population and the variant allele frequency was found as 0.095. According to reduced sex hormone-binding globulin levels and increased free androgen index in the present study, obesity was linked with hyperandrogenism in female subjects. Both polymorphisms were investigated as potential genetic susceptibility markers for obesity and neither DENND1A nor CYP19A1 showed any associations.